A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Inclusion Criteria:

1. Written informed consent
2. Aged 18 or above
3. Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation.
4. Documented PD-L1 expression by PD-L1 IHC per local report.
5. Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
6. Part C and Part D: No prior I/O treatment for NSCLC.
7. ECOG performance status of 0 or 1 at enrolment.
8. Life expectancy of ≥ 12 weeks at enrolment.
9. Have at least 1 measurable lesion per RECIST v1.1.
10. Adequate bone marrow, liver and kidney function

Exclusion Criteria:

1. Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
2. Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
3. Previous treatment with an anti-TIGIT therapy
4. Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
5. Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
6. Part C and Part D: Any prior systemic treatment with an immune-oncology agent (Treatment with one previous systemic chemotherapy will be allowed).
7. Primary or secondary resistance after treatment with 2 or more regimens including a CPI.
8. Symptomatic central nervous system (CNS) metastasis.
9. Thromboembolic event within 3 months prior to enrolment.
10. Other invasive malignancy within 2 years prior to screening.